Supplementary Figures 1 - 8 from Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy

Supplementary Figure 1. SPADE plots of normal bone marrow sample no. 6. Supplementary Figure 2. The frequency of cells in the indicated (manually-gated) populations. Supplementary Figure 3. Multi-dimensional binning analysis of the CD34+CD38 low subset confirmed that distinct karyotype and genotype-specific immunophenotypic patterns are observed in high-dimensional space. Supplementary Figure 4. AML subtypes are characterized by distinct phosphoprotein signaling patterns. Supplementary Figure 5. viSNE analysis of CD34+CD38 low subset demonstrates signaling aberrancy is most pronounced in cells outside the viSNE space occupied by normal cells. Supplementary Figure 6. Median basal intracellular signaling of CD34+CD38low cells from AML samples of each subtype. Supplementary Figure 7. HU treatment does not increase the fraction of apoptotic cells measured by cPARP levels. Supplementary Figure 8. Histone 3 lysine 9 acetylation decreases with immunophenotypic differentiation in both normal and AML patient samples.